First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN RU |
| Published: |
Endocrinology Research Centre
2016
|
| Subjects: | |
| Online Access: | https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|